Progress in medical treatment of ovarian cancer_West China Medical Journal

Authors：

HAN Jinbiao ^1,2 , LI Kemin ^1,2 , HU Xia ^1,2 ,  YIN Rutie ^1,2

1. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

YIN Rutie, Email: yrtt2013@163.com

Keywords：

Ovarian cancer; Poly adenosine diphosphate-ribose polymerase inhibitors; Immunotherapy; Antiangiogenic drugs

DOI：

10.7507/1002-0179.201909026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The mortality rate of ovarian cancer is the highest among female reproductive tract malignancies. Although most patients have undergone recurrent treatments such as surgery, chemotherapy, and targeted therapy, the recurrence rate is still high. The exploration of scholars in this field has never stopped. In recent years, remarkable achievements have been made in the medical treatment of ovarian cancer. The research of poly adenosinediphosphate-ribose polymerase, immunotherapy (immunocheckpoint inhibitor monotherapy, immune checkpoint inhibitor combined with other drugs) and anti-angiogenic drugs have provided new methods for the treatment of this disease, and throughout the whole process of ovarian cancer treatment. This paper summarizes this, and aims to provide a reference for the clinical treatment of ovarian cancer.

Citation： HAN Jinbiao, LI Kemin, HU Xia, YIN Rutie. Progress in medical treatment of ovarian cancer. West China Medical Journal, 2021, 36(3): 406-411. doi: 10.7507/1002-0179.201909026 Copy

1.	Huang L, Xu AM. SET and MYND domain containing protein 3 in cancer. Am J Transl Res, 2017, 9(1): 1-14.
2.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA CancerJ Clin, 2018, 68(1): 7-30.
3.	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
4.	Zeighami S, Soltani M, Khajeh F, et al. Testicular papillary serous carcinoma of ovarian type, a rare case report, however an important timely diagnostic issue. Urol Case Rep, 2020, 33: 101301.
5.	Nagtegaal SHJ, Hulsbergen AFC, van Dorst EBL, et al. Age, pathology and CA-125 are prognostic factors for survival in patients with brain metastases from gynaecological tumours. Clin Transl Radiat Oncol, 2020, 24: 11-15.
6.	Hu X, Xia M, Wang J, et al. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. Biomed Pharmacother, 2020, 129: 110397.
7.	Lima MA, Silva SV, Jaeger RG, et al. Progesterone decreases ovarian cancer cells migration and invasion. Steroids, 2020, 161: 108680.
8.	Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet, 2008, 124(1): 31-42.
9.	Bai HL, Kang CM, Sun ZQ, et al. TTDA inhibited apoptosis by regulating the p53-Bax/Bcl2 axis in glioma. Exp Neurol, 2020, 331: 113380.
10.	Godthelp BC, Wiegant WW, Waisfisz Q, et al. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res, 2006, 594(1/2): 39-48.
11.	Lukanović D, Herzog M, Kobal B, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed Pharmacother, 2020, 129: 110401.
12.	Hadjidemetriou M, Papafilippou L, Unwin RD, et al. Nano-scavengers for blood biomarker discovery in ovarian carcinoma. Nano Today, 2020, 34: 100901.
13.	Sim WC, Lee CY, Richards R, et al. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing. Exp Mol Pathol, 2020, 116: 104483.
14.	Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol, 2016, 140(2): 199-203.
15.	Tong L, Cao W, Sheng J, et al. RDM1 plays an oncogenic role in human ovarian carcinoma cells. Artif Cells Nanomed Biotechnol, 2020, 48(1): 885-892.
16.	Huang P, Wang G, Wang Z, et al. Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy. Colloids Surf B Biointerfaces, 2020, 194: 111164.
17.	Yoon JH, Shin JW, Pham TH, et al. Methyl lucidone induces apoptosis and G2/M phase arrest via the PI3K/Akt/NF-κB pathway in ovarian cancer cells. Pharm Biol, 2020, 58(1): 51-59.
18.	Chen M, Ding Y, Ke Y, et al. Anti-tumour activity of zinc ionophore pyrithione in human ovarian cancer cells through inhibition of proliferation and migration and promotion of lysosome-mitochondrial apoptosis. Artif Cells Nanomed Biotechnol, 2020, 48(1): 824-833.
19.	Martin-Lluesma S, Graciotti M, Grimm AJ, et al. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Curr Opin Biotechnol, 2020, 65: 190-196.
20.	Tavsan Z, Ayar Kayali H. EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance. Cell Adh Migr, 2020, 14(1): 57-68.
21.	Moioli M, Barra F, Maramai M, et al. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs. Expert Opin Investig Drugs, 2019, 28(12): 1025-1029.
22.	Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon, 2019, 5(12): e02826.
23.	MacGregor HL, Sayad A, Elia A, et al. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. J Immunother Cancer, 2019, 7(1): 357.
24.	Jeong SY, Choi CH, Kim TJ, et al. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. J Ovarian Res, 2019, 13(1): 1.
25.	Zhang C, Li X, Jin S, et al. The anti-proliferative effect of flavonoid nanoparticles on the human ovarian cancer cell line SK0V3. J Nanosci Nanotechnol, 2020, 20(10): 6040-6046.
26.	Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med, 2012, 366(15): 1382-1392.
27.	Gore M, Hackshaw A, Brady WE, et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol, 2019, 153(3): 541-548.
28.	Chen Z, Guo X, Sun S, et al. Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. Bioengineered, 2020, 11(1): 311-317.
29.	Yang X, Yan Y, Chen Y, et al. Expression of concern: involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-b-glucopyranoside on ovarian cancer cells. Artif Cells Nanomed Biotechnol, 2020, 48(1): 748.
30.	Zhang L, Jin Y, Yang H, et al. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination. Carcinogenesis, 2019, 40(12): 1492-1503.
31.	Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol, 2019, 5(3): 393-401.
32.	Shopov S. A collision between fibroma and serous ovarian cystadenoma mimicking carcinoma. Folia Med (Plovdiv), 2019, 61(4): 634-638.
33.	Yoshida K, Yokoi A, Kagawa T, et al. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. Carcinogenesis, 2019, 40(12): 1435-1444.
34.	Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol, 2019, 20(5): 636-648.
35.	Lee EK, Xiong N, Cheng SC, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial. Gynecol Oncol, 2020, 159(1): 72-78.
36.	Liu W, Tian X, Ding X, et al. Expression of dual-specificity phosphatase 2 (DUSP2) in patients with serous ovarian carcinoma and in SKOV3 and OVCAR3 cells in vitro. Med Sci Monit, 2019, 25: 10180-10189.
37.	Choi HJ, Armaiz Pena GN, Pradeep S, et al. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev, 2015, 34(1): 19-40.
38.	Zhang M, Xia B, Xu Y, et al. Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis. Artif Cells Nanomed Biotechnol, 2019, 47(1): 1224-1233.
39.	Colombo I, Garg S, Danesh A, et al. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient. Cold Spring Harb Mol Case Stud, 2019, 5(6): a004341.
40.	Brown J, Drury L, Crane EK, et al. When less is more: minimally invasive surgery compared with laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer. J Minim Invasive Gynecol, 2019, 26(5): 902-909.
41.	Lee JY, Kim K, Lee YS, et al. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. Gynecol Oncol, 2016, 143(3): 622-627.
42.	Jørgensen TL, Herrstedt J, Academy of Geriatric Cancer Research (AgeCare), et al. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. J Geriatr Oncol, 2020, 11(4): 593-602.
43.	Kundalia K, Nagarajan G, Tongaonkar H, et al. Resection of hepatic metastasis as a part of ultra-radical surgery for epithelial ovarian cancer - a single institution experience. HPB, 2019, 21: S383.
44.	Alotaibi MR, As Sobeai HM, Alaqil FA, et al. A newly synthesized platinum-based compound (PBC-Ⅱ) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy. Saudi Pharm J, 2019, 27(8): 1203-1209.
45.	Xu L, Wu Y, Che X, et al. Cox-LASSO analysis reveals a ten-lncRNA signature to predict outcomes in patients with high-grade serous ovarian cancer. DNA Cell Biol, 2019, 38(12): 1519-1528.
46.	Liu H, Chen Y, Liu L. Unusual uptake of ¹³¹iodine in bilateral ovarian endometriosis cysts in a patient with thyroid cancer. Endocrine, 2019, 66(3): 693-694.
47.	Gong Z, Shen X, Yang J, et al. FSH receptor binding inhibitor up-regulates ARID1A and PTEN genes associated with ovarian cancers in mice. Braz J Med Biol Res, 2019, 52(7): e8381.
48.	Zhong H, Macdougall J, Chui D, et al. CR012, a secretory leukocyte protease inhibitor (SLPI) neutralizing fully human monoclonal antibody inhibits the growth of colon carcinoma in vitro and in vivo. (2006-04-05)[2019-09-04]. https://cancerres.aacrjournals.org/content/66/8_Supplement/1082.3.
49.	Jeng KS, Sheen IS, Jeng WJ, et al. Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: an in vivo study. Oncol Lett, 2012, 4(6): 1158-1162.
50.	Scaletta G, Quagliozzi L, Cianci S, et al. Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience. Updates Surg, 2019, 71(4): 729-734.
51.	Gho YS, Lee JE, Oh KS, et al. Development of antiangiogenin peptide using a phage-displayed peptide library. Cancer Res, 1997, 57(17): 3733-3740.
52.	谢宇锋, 盛伟华, 缪竞诚, 等. 人IL-17F对裸鼠人肝癌移植瘤生长的影响. 生物工程学报, 2006(5): 772-778.
53.	Kopreski MS. Method enabling use of extracellular RNA extracted from plasmaor serum to detect, monitor or evaluate cancer. (2010-03-11)[2019-09-04]. https://www.freepatentsonline.com/EP0938320.html.
54.	Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol, 2016, 56(2): 157-169.
55.	Pandya D, Camacho SC, Padron MM, et al. Rapid development and use of patient-specific ctDNA biomarkers to avoid a “rash decision” in an ovarian cancer patient. Cold Spring Harb Mol Case Stud, 2019, 5(6): a004648.
56.	Hamam R, Hamam D, Alsaleh KA, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis, 2017, 8(9): e3045.

1. Huang L, Xu AM. SET and MYND domain containing protein 3 in cancer. Am J Transl Res, 2017, 9(1): 1-14.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA CancerJ Clin, 2018, 68(1): 7-30.
3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
4. Zeighami S, Soltani M, Khajeh F, et al. Testicular papillary serous carcinoma of ovarian type, a rare case report, however an important timely diagnostic issue. Urol Case Rep, 2020, 33: 101301.
5. Nagtegaal SHJ, Hulsbergen AFC, van Dorst EBL, et al. Age, pathology and CA-125 are prognostic factors for survival in patients with brain metastases from gynaecological tumours. Clin Transl Radiat Oncol, 2020, 24: 11-15.
6. Hu X, Xia M, Wang J, et al. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. Biomed Pharmacother, 2020, 129: 110397.
7. Lima MA, Silva SV, Jaeger RG, et al. Progesterone decreases ovarian cancer cells migration and invasion. Steroids, 2020, 161: 108680.
8. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet, 2008, 124(1): 31-42.
9. Bai HL, Kang CM, Sun ZQ, et al. TTDA inhibited apoptosis by regulating the p53-Bax/Bcl2 axis in glioma. Exp Neurol, 2020, 331: 113380.
10. Godthelp BC, Wiegant WW, Waisfisz Q, et al. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res, 2006, 594(1/2): 39-48.
11. Lukanović D, Herzog M, Kobal B, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed Pharmacother, 2020, 129: 110401.
12. Hadjidemetriou M, Papafilippou L, Unwin RD, et al. Nano-scavengers for blood biomarker discovery in ovarian carcinoma. Nano Today, 2020, 34: 100901.
13. Sim WC, Lee CY, Richards R, et al. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing. Exp Mol Pathol, 2020, 116: 104483.
14. Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol, 2016, 140(2): 199-203.
15. Tong L, Cao W, Sheng J, et al. RDM1 plays an oncogenic role in human ovarian carcinoma cells. Artif Cells Nanomed Biotechnol, 2020, 48(1): 885-892.
16. Huang P, Wang G, Wang Z, et al. Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy. Colloids Surf B Biointerfaces, 2020, 194: 111164.
17. Yoon JH, Shin JW, Pham TH, et al. Methyl lucidone induces apoptosis and G2/M phase arrest via the PI3K/Akt/NF-κB pathway in ovarian cancer cells. Pharm Biol, 2020, 58(1): 51-59.
18. Chen M, Ding Y, Ke Y, et al. Anti-tumour activity of zinc ionophore pyrithione in human ovarian cancer cells through inhibition of proliferation and migration and promotion of lysosome-mitochondrial apoptosis. Artif Cells Nanomed Biotechnol, 2020, 48(1): 824-833.
19. Martin-Lluesma S, Graciotti M, Grimm AJ, et al. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Curr Opin Biotechnol, 2020, 65: 190-196.
20. Tavsan Z, Ayar Kayali H. EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance. Cell Adh Migr, 2020, 14(1): 57-68.
21. Moioli M, Barra F, Maramai M, et al. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs. Expert Opin Investig Drugs, 2019, 28(12): 1025-1029.
22. Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon, 2019, 5(12): e02826.
23. MacGregor HL, Sayad A, Elia A, et al. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. J Immunother Cancer, 2019, 7(1): 357.
24. Jeong SY, Choi CH, Kim TJ, et al. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. J Ovarian Res, 2019, 13(1): 1.
25. Zhang C, Li X, Jin S, et al. The anti-proliferative effect of flavonoid nanoparticles on the human ovarian cancer cell line SK0V3. J Nanosci Nanotechnol, 2020, 20(10): 6040-6046.
26. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med, 2012, 366(15): 1382-1392.
27. Gore M, Hackshaw A, Brady WE, et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol, 2019, 153(3): 541-548.
28. Chen Z, Guo X, Sun S, et al. Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. Bioengineered, 2020, 11(1): 311-317.
29. Yang X, Yan Y, Chen Y, et al. Expression of concern: involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-b-glucopyranoside on ovarian cancer cells. Artif Cells Nanomed Biotechnol, 2020, 48(1): 748.
30. Zhang L, Jin Y, Yang H, et al. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination. Carcinogenesis, 2019, 40(12): 1492-1503.
31. Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol, 2019, 5(3): 393-401.
32. Shopov S. A collision between fibroma and serous ovarian cystadenoma mimicking carcinoma. Folia Med (Plovdiv), 2019, 61(4): 634-638.
33. Yoshida K, Yokoi A, Kagawa T, et al. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. Carcinogenesis, 2019, 40(12): 1435-1444.
34. Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol, 2019, 20(5): 636-648.
35. Lee EK, Xiong N, Cheng SC, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial. Gynecol Oncol, 2020, 159(1): 72-78.
36. Liu W, Tian X, Ding X, et al. Expression of dual-specificity phosphatase 2 (DUSP2) in patients with serous ovarian carcinoma and in SKOV3 and OVCAR3 cells in vitro. Med Sci Monit, 2019, 25: 10180-10189.
37. Choi HJ, Armaiz Pena GN, Pradeep S, et al. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev, 2015, 34(1): 19-40.
38. Zhang M, Xia B, Xu Y, et al. Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis. Artif Cells Nanomed Biotechnol, 2019, 47(1): 1224-1233.
39. Colombo I, Garg S, Danesh A, et al. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient. Cold Spring Harb Mol Case Stud, 2019, 5(6): a004341.
40. Brown J, Drury L, Crane EK, et al. When less is more: minimally invasive surgery compared with laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer. J Minim Invasive Gynecol, 2019, 26(5): 902-909.
41. Lee JY, Kim K, Lee YS, et al. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. Gynecol Oncol, 2016, 143(3): 622-627.
42. Jørgensen TL, Herrstedt J, Academy of Geriatric Cancer Research (AgeCare), et al. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. J Geriatr Oncol, 2020, 11(4): 593-602.
43. Kundalia K, Nagarajan G, Tongaonkar H, et al. Resection of hepatic metastasis as a part of ultra-radical surgery for epithelial ovarian cancer - a single institution experience. HPB, 2019, 21: S383.
44. Alotaibi MR, As Sobeai HM, Alaqil FA, et al. A newly synthesized platinum-based compound (PBC-Ⅱ) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy. Saudi Pharm J, 2019, 27(8): 1203-1209.
45. Xu L, Wu Y, Che X, et al. Cox-LASSO analysis reveals a ten-lncRNA signature to predict outcomes in patients with high-grade serous ovarian cancer. DNA Cell Biol, 2019, 38(12): 1519-1528.
46. Liu H, Chen Y, Liu L. Unusual uptake of ¹³¹iodine in bilateral ovarian endometriosis cysts in a patient with thyroid cancer. Endocrine, 2019, 66(3): 693-694.
47. Gong Z, Shen X, Yang J, et al. FSH receptor binding inhibitor up-regulates ARID1A and PTEN genes associated with ovarian cancers in mice. Braz J Med Biol Res, 2019, 52(7): e8381.
48. Zhong H, Macdougall J, Chui D, et al. CR012, a secretory leukocyte protease inhibitor (SLPI) neutralizing fully human monoclonal antibody inhibits the growth of colon carcinoma in vitro and in vivo. (2006-04-05)[2019-09-04]. https://cancerres.aacrjournals.org/content/66/8_Supplement/1082.3.
49. Jeng KS, Sheen IS, Jeng WJ, et al. Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: an in vivo study. Oncol Lett, 2012, 4(6): 1158-1162.
50. Scaletta G, Quagliozzi L, Cianci S, et al. Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience. Updates Surg, 2019, 71(4): 729-734.
51. Gho YS, Lee JE, Oh KS, et al. Development of antiangiogenin peptide using a phage-displayed peptide library. Cancer Res, 1997, 57(17): 3733-3740.
52. 谢宇锋, 盛伟华, 缪竞诚, 等. 人IL-17F对裸鼠人肝癌移植瘤生长的影响. 生物工程学报, 2006(5): 772-778.
53. Kopreski MS. Method enabling use of extracellular RNA extracted from plasmaor serum to detect, monitor or evaluate cancer. (2010-03-11)[2019-09-04]. https://www.freepatentsonline.com/EP0938320.html.
54. Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol, 2016, 56(2): 157-169.
55. Pandya D, Camacho SC, Padron MM, et al. Rapid development and use of patient-specific ctDNA biomarkers to avoid a “rash decision” in an ovarian cancer patient. Cold Spring Harb Mol Case Stud, 2019, 5(6): a004648.
56. Hamam R, Hamam D, Alsaleh KA, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis, 2017, 8(9): e3045.

Previous Article
Research progress of serum C-reactive protein, prealbumin and their ratio in gastric cancer
Next Article
新型冠状病毒肺炎产妇体外膜肺氧合辅助下的镇静一例

West China Medical Journal

Progress in medical treatment of ovarian cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content